Concordia International (CXR) Trading Down 2.4%

Concordia International Corp (TSE:CXR) (NASDAQ:CXRX) was down 2.4% during trading on Thursday . The company traded as low as C$0.77 and last traded at C$0.80. Approximately 81,286 shares were traded during mid-day trading, a decline of 57% from the average daily volume of 188,021 shares. The stock had previously closed at C$0.82.

The firm has a market capitalization of $40.63, a PE ratio of -0.02 and a beta of -1.65.

Concordia International (TSE:CXR) (NASDAQ:CXRX) last announced its quarterly earnings data on Tuesday, November 14th. The company reported C$0.08 EPS for the quarter, missing the Zacks’ consensus estimate of C$0.17 by C($0.09).

COPYRIGHT VIOLATION NOTICE: “Concordia International (CXR) Trading Down 2.4%” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at

About Concordia International

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.

Receive News & Ratings for Concordia International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia International and related companies with's FREE daily email newsletter.

Leave a Reply